Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

EXOZBullishCorporate Developmentsnews

High materiality8/10

EXOZymes Secures $2.03M NIH SBIR to Expand Cannabinoid Pipeline

Jun 24, 2026, 4:14 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive non-dilutive funding supports cash runway and validates platform; could lift valuation and drive licensing discussions; SBIR awards have historically spurred speculative upside in biotech micro-caps.

AI summary

What happened, with direct paths to the underlying reporting

eXoZymes has been awarded a Phase IIB SBIR grant totaling $2,028,518 from NIH’s NIGMS, with work starting July 1, 2026. The award adds a second biosolution to the pipeline, focusing on producing rare cannabinoids and analogs via a cell-free manufacturing platform. With non-dilutive funding approaching $20 million, the company sees expanded paths to partnerships and licensing without shareholder dilution.

NIH SBIR grant of $2.028M awarded to EXOZymes.
Grant begins July 1, 2026; second biosolution after NCT.
Total non-dilutive funding near $20M validates scalable platform.
U.S. minor cannabinoids market to $33.3B by 2030 supports upside.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.